Author | Year | Phase | Disease stage | n | RT dose | Conc. CHT | Adj. CHT | pCR rate (%) | Downst | Tox gr.3+ | Postop. c |
|---|
Valentini [96] | 2008 | IIb | T3 | 164 | 50.4 | Cis/5-FU | dis.4 | 226 | 52%7 | 7% | 10%10 |
| | | | | | 50.4 | Ox + Ralti | dis.4 | 286 | 58%7 | 16% | 6%10 |
Stojanovic [97] | 2011 | II | T3/4 or N+ | 49 | 45 | Cap + MMC | 5-FU/LV | 16 | 27%7 | n.r | 16% |
Jeong [98] | 2016 | I | T3/4 or N+ | 22 | 50.4 | Cap + Tem (esc) | n.s | 325 | n.r | 18% | n.r |
Jakobsen [99] | 2008 | II | T3/4 | 35 | 602 | UFT + Cele | n.s | 21 | n.r | 6% (49%9) | n.r |
Debucquoy [100] | 2009 | II, rand | T3/4 or N+ | 35 | 45 | 5-FU ci + Cele | dis | 396 | n.r | 0% | n.r |
| | | | | | | 5-FU ci | | 296 | n.r | 3% | n.r |
Wang [101] | 2014 | II | T3/4 or N+ | 53 | 44 | UFT + FA + Cele | FOLFOX | 13 | n.r | 6% (gr. 4) | n.r |
O´Neil [102] | 2010 | I | T3/4 or N+ | 10 | 50.4 | 5-FU ci + Borte (esc) | n.s | 10 | 40%7 | DLT 40% | n.r |
Buijsen [103] | 2013 | I | T3/4 or N+ | 11 | 50.4 | Cap + Nel (esc) | n.s | 27 | 82%7 | 55% | 9% |
Meyer [104] | 2018 | I | T3/4 or N+ | 14 | 50.4 | Cap + Bavi (esc) | dis | 7 | 64%8 | 25% | 21% |
von Moos [105] | 2018 | I/II | T3/4 or N+1 | 54 | 45 | Cap + Sor (esc) | rec | 15 | n.r | n.r | 13% |
Kim [106] | 2016 | I | T3/4 or N+ | 17 | 50.4 | 5-FU ci + Sor (esc) | n.s | 33 | 87%8 | 18% | n.r |
Czito [107] | 2017 | Ib | T3/4 or N+ | 32 | 50.4 | Cap + Veli (esc) | rec | 29 | 71%7 | 25% | n.r |
Bendell [108] | 2017 | II | T3/4 or N+ | 39 | 50.4 | 5-FU + Afli | FOLFOX + Afli | 23 | n.r | n.r | 11% |
- n = number of patients, RT dose: radiation dose in Gy, conc. CHT: concurrent chemotherapy, adj. CHT: adjuvant chemotherapy, pCR rate: percentage of patients with pathologic complete regression, downstaging: percentage of patients with major downstaging defined according to study protocol (only listed if combined T and N downstaging was reported), tox gr.3+: acute grade 3+ toxicity during chemoradiation (only listed if an overall percentage was reported), postop. c.: postoperative complications grade 3+ (only listed if an overall percentage was reported), rand.: randomized, Cap: Capecitabine, MMC: Mitomycin C, esc: dose escalated, 5-FU: 5-fluorouracil, ci: contineous infusion, UFT: uracil-tegafur, FA: folinic acid, Cis: Cisplatin, Ox: Oxaliplatin, CAPOX: combination regimen including capecitabine and oxaliplatin, LV: leukovorin, Tem: Temozolomide, Cele: Celecoxib, Ralti: Raltitrexed, Borte: Bortezomib, Nel: Nelfinavir, Bavi: Bavituximab, Sor: Sorafenib, Veli: Veliparib, Afli: Aflibercept, n.s.: not specified, dis.: at the discretion of the treating physician, FOLFOX: combination regimen including 5-fluorouracil, leucovorine and oxaliplatin, rec.: recommended, n.r.: not reported, gr.: grade, DLT: dose limiting toxicity as predefined in the protocol, bold style: indicates significant difference, 1: only KRAS mutant patients included, 2: patients received an additional brachytherapy boost with 5 Gy in 1 fraction, 3: patients recived one consolidation cycle of CAPOX prior to surgery, 4: recommended only for ypN+ patients, 5: significantly increased pCR rate in n = 16 patients with methylated MGMT promotor compared to n = 6 patients without MGMT methylation (38% vs 17%), 6: no significant difference, 7: downstaging defined as yp stage 0–1, 8: downstaging defined as reduction of yp stage compared to c stage, 9: treatment with celecoxib finished due to rash (although all grade 1–2), 10: anastomotic leakage
